AFNT-212

N/A

Report date: 2024/03/19 15:36:23

Base Information

Drug NameAFNT-212
Drug Alias NameAFNT-212
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsKRAS G12D inhibitors +[6] 
TargetsKRAS G12DKRAS G12CPhosphatidylinositol 3 kinase alpha +[4] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffini-T Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffini-T Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A